144 related articles for article (PubMed ID: 20845812)
21. Treatment options for renal cell carcinoma in patients with von Hippel-Lindau disease.
Tsimafeyeu I; Demidov L
J Cancer Res Ther; 2010; 6(4):575-7. PubMed ID: 21358107
[TBL] [Abstract][Full Text] [Related]
22. Survival in Patients With Primary Metastatic Renal Cell Carcinoma Treated With Sunitinib With or Without Previous Cytoreductive Nephrectomy: Results From a Population-based Registry.
de Groot S; Redekop WK; Sleijfer S; Oosterwijk E; Bex A; Kiemeney LA; Uyl-de Groot CA
Urology; 2016 Sep; 95():121-7. PubMed ID: 27179773
[TBL] [Abstract][Full Text] [Related]
23. Complete cerebral response with sunitinib for metastatic renal cell carcinoma.
Medioni J; Cojocarasu O; Belcaceres JL; Halimi P; Oudard S
Ann Oncol; 2007 Jul; 18(7):1282-3. PubMed ID: 17675397
[No Abstract] [Full Text] [Related]
24. Sunitinib rechallenge with dose escalation in progressive metastatic renal cell carcinoma: A case report and literature review.
Zhang X; Shen P; Yao J; Chen N; Liu J; Zeng H
Medicine (Baltimore); 2018 Aug; 97(31):e11565. PubMed ID: 30075524
[TBL] [Abstract][Full Text] [Related]
25. 11C-acetate PET for early prediction of sunitinib response in metastatic renal cell carcinoma.
Maleddu A; Pantaleo MA; Castellucci P; Astorino M; Nanni C; Nannini M; Busato F; Di Battista M; Farsad M; Lodi F; Boschi S; Fanti S; Biasco G
Tumori; 2009; 95(3):382-4. PubMed ID: 19688982
[TBL] [Abstract][Full Text] [Related]
26. Cytoreductive radiofrequency ablation in patients with metastatic renal cell carcinoma (RCC) with small primary tumours treated with sunitinib or interferon-α.
Tsimafeyeu I; Zart JS; Chung B
BJU Int; 2013 Jul; 112(1):32-8. PubMed ID: 23746142
[TBL] [Abstract][Full Text] [Related]
27. Recovery of paraneoplastic hypercalcemia by sunitinib treatment for renal cell carcinoma: a case report and review of the literature.
Karaca H; Lale A; Dikilitas M; Ozkan M; Er O
Med Oncol; 2010 Sep; 27(3):1023-6. PubMed ID: 19830602
[TBL] [Abstract][Full Text] [Related]
28. Prognostic significance of cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma treated with first-line sunitinib: a European multiinstitutional study.
Bamias A; Tzannis K; Papatsoris A; Oudard S; Beuselinck B; Escudier B; Liontos M; Elaidi TR; Chrisofos M; Stravodimos K; Anastasiou I; Mitropoulos D; Deliveliotis C; Constantinides C; Dimopoulos MA; Bamia C
Clin Genitourin Cancer; 2014 Oct; 12(5):373-83. PubMed ID: 24819319
[TBL] [Abstract][Full Text] [Related]
29. Patients with metastatic renal cell carcinoma with long-term disease-free survival after treatment with sunitinib and resection of residual metastases.
Rini BI; Shaw V; Rosenberg JE; Kim ST; Chen I
Clin Genitourin Cancer; 2006 Dec; 5(3):232-4. PubMed ID: 17239278
[TBL] [Abstract][Full Text] [Related]
30. [Metastasis to the Tongue from Renal Cell Carcinoma 10 Years after Nephrectomy : A Case Report].
Wang C; Takeda K; Shiba M; Takayama H; Munakata S
Hinyokika Kiyo; 2016 Aug; 62(8):407-10. PubMed ID: 27624106
[TBL] [Abstract][Full Text] [Related]
31. Long-term response with sunitinib for metastatic renal cell carcinoma.
Ronnen EA; Kondagunta GV; Ginsberg MS; Russo P; Motzer RJ
Urology; 2006 Sep; 68(3):672.e19-20. PubMed ID: 16979716
[TBL] [Abstract][Full Text] [Related]
32. Adjuvant sunitinib for high-risk-resected renal cell carcinoma: a meta-analysis of ASSURE and S-TRAC trials.
Gyawali B; Ando Y
Ann Oncol; 2017 Apr; 28(4):898-899. PubMed ID: 27993814
[No Abstract] [Full Text] [Related]
33. Sunitinib treatment in patients with severe renal function impairment: a report of four cases by the Hellenic Cooperative Oncology Group.
Lainakis G; Bamias A; Psimenou E; Fountzilas G; Dimopoulos MA
Clin Nephrol; 2009 Jul; 72(1):73-8. PubMed ID: 19640391
[TBL] [Abstract][Full Text] [Related]
34. Sunitinib for treatment of advanced renal cell cancer: primary tumor response.
van der Veldt AA; Meijerink MR; van den Eertwegh AJ; Bex A; de Gast G; Haanen JB; Boven E
Clin Cancer Res; 2008 Apr; 14(8):2431-6. PubMed ID: 18413834
[TBL] [Abstract][Full Text] [Related]
35. Neoadjuvant sunitinib facilitates nephron-sparing surgery and avoids long-term dialysis in a patient with metachronous contralateral renal cell carcinoma.
Ansari J; Doherty A; McCafferty I; Wallace M; Deshmukh N; Porfiri E
Clin Genitourin Cancer; 2009 Aug; 7(2):E39-41. PubMed ID: 19692322
[TBL] [Abstract][Full Text] [Related]
36. Predictive role of tissue-based molecular markers in patients treated with sunitinib for metastatic renal cell carcinoma.
You D; Song SH; Cho YM; Lee JL; Jeong IG; Song C; Hong JH; Kim CS; Ahn H
World J Urol; 2015 Jan; 33(1):111-8. PubMed ID: 24710685
[TBL] [Abstract][Full Text] [Related]
37. Prognostic effect of cytoreductive nephrectomy in synchronous metastatic renal cell carcinoma: a comparative study using inverse probability of treatment weighting.
Klatte T; Fife K; Welsh SJ; Sachdeva M; Armitage JN; 'Aho T; Riddick AC; Matakidou A; Eisen T; Stewart GD
World J Urol; 2018 Mar; 36(3):417-425. PubMed ID: 29256020
[TBL] [Abstract][Full Text] [Related]
38. Treatment strategies for advanced renal cell carcinoma: A new paradigm for surgical treatment.
Tomita Y
Int J Urol; 2016 Jan; 23(1):13-21. PubMed ID: 26347163
[TBL] [Abstract][Full Text] [Related]
39. Progression of a caval vein thrombus in two patients with primary renal cell carcinoma on pretreatment with sunitinib.
Bex A; Van der Veldt AA; Blank C; Meijerink MR; Boven E; Haanen JB
Acta Oncol; 2010 May; 49(4):520-3. PubMed ID: 20105087
[No Abstract] [Full Text] [Related]
40. Does timing of cytoreductive nephrectomy impact patient survival with metastatic renal cell carcinoma in the tyrosine kinase inhibitor era? A multi-institutional study.
Stroup SP; Raheem OA; Palazzi KL; Liss MA; Mehrazin R; Kopp RP; Patel N; Cohen SA; Park SK; Patterson AL; Kane CJ; Millard F; Derweesh IH
Urology; 2013 Apr; 81(4):805-11. PubMed ID: 23414694
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
